Endocrine Abstracts

Background: World Gastroenterology Organisation (WGO) quotes gallstones prevalence of 9-21%, incidence of 0.63/100 persons/year in Europe; 10-15% of UK population have gallstones (1). Acromegaly patients’ prevalence is 8.3% and 35% developing incidental gallstones during somatostatin analogue (SSA) treatment (2).Objective: To evaluate the prevalence of gallstones in SSA treated Acromegaly patients in University Hospitals of Leicester (UHL).<p cl...

Background: Radiotherapy is a third line treatment in Acromegaly. Pituitary radiotherapy (RT) is known to have cardiovascular complications (MI/IHD, CCF & CVA) due to radiation effects on normal pituitary and surrounding structures over and above the excess Growth hormone risk on metabolism (1).Objective: To compare RT vs non-RT treated Acromegaly cohorts’ cardiovascular (CV) outcomes in unselected consecutive Acromegaly patients.<p class="a...

Background: Dopamine agonists (DA) are included in the management algorithm of acromegaly. Studies on cabergoline monotherapy report IGF-1 normalisation in between 0% and 100% of the patients during treatment periods ranging between 2.6 and 24 months. However, in many of these studies, previous radiotherapy is a confounding factor. Furthermore, real world data applying the current disease control criteria (normal IGF-1 and GH<1 mg/l) are not available. The aim of this stud...

Background: Adrenal crisis is a life threatening emergency with an incidence of 5–10 adrenal crises/100 patient-years with mortality around 0.5/100 patient-years.Objective: Audit of inpatient adrenal crisis management was undertaken in line with Society for Endocrinology (SFE) guidance 2016 (Trust audit No:9763).Methods: Retrospective evaluation of electronic and paper case records of 2 years (January 2017–December 2018)....

Background: British Association of Thyroid and Endocrine Surgeons defines post-operative hypocalcaemia as adjusted calcium of < 2.0 mmol/l; ‘late hypocalcaemia’ as the ongoing requirement for calcium/Vitamin D supplements at 6 months; permanent post-surgical hypoparathyroidism (PSHP) at 12 months. The incidence rates of late hypocalcaemia are 6.5–12.1% and PSHP is 0.9%–4.5%.Objective: To evaluate PSHP incidence rate in total thyro...

Background: Cabergoline monotherapy or in combination with somatostatin analogue (SSA) has been reported in few studies with IGF-1-normalization-rates 0%-100%(monotherapy) and 42%-60%(combination therapy). However, in these studies, inclusion of irradiated patients is a potential confounder and currently proposed disease control criteria (normal IGF-1, GH<1 mg/l) have not been applied.Aim: Investigate the efficacy of cabergoline monotherapy or as add...

Background: Current conclusions on risk of second brain tumour following radiotherapy for pituitary adenoma or craniopharyngioma are challenged methodologically by small patient sample size, selection biases or lack of appropriate controls.Objective: To ascertain whether radiotherapy for pituitary adenoma or craniopharyngioma is associated with increased second brain tumour risk, through use of appropriate methodology.Design: Multi...

Background: The risk of a second brain tumour following radiotherapy for pituitary adenoma or craniopharyngioma in adults is currently unclear. Studies are methodologically limited by small patient sample size, few case events, selection biases or the use of inappropriate controls.Objective: To ascertain whether radiotherapy delivered to adults with pituitary adenoma or craniopharyngioma is associated with an increased second brain tumour risk using appr...

Background: The published data on the natural history of (presumed) non-functioning pituitary microadenomas (micro-NFAs) is possibly compromised by small sample sizes, short follow-up and inclusion of cases with other pathologies in the analyses.Objective: To clarify the long-term outcomes of micro-NFAs in a large cohort of patients.Methods: We conducted a multi-centre, retrospective, cohort study involving 22 UK endocrine departme...

Background: Large series of patients elucidating the natural history of conservatively managed non-functioning pituitary macroadenomas (macroNFPAs) and relevant prognostic factors are not available.Objectives: Clarify long-term outcomes of macroNFPAs in large cohort of patients.Methods: Multi-centre [21 UK endocrine departments-UK NFPA consortium], retrospective, cohort study of ca...